Tags

Type your tag names separated by a space and hit enter

Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis

Abstract
The objective of this review is to perform a systematic review of the beneficial and harmful effects of edaravone for the treatment of amyotrophic lateral sclerosis.

Publisher

Canadian Agency for Drugs and Technologies in Health
Ottawa (ON)

Language

eng

PubMed ID

31206286

Citation

Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Canadian Agency for Drugs and Technologies in Health, 2019, Ottawa (ON).
Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
(2019). In Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
* Article titles in AMA citation format should be in sentence-case
TY - BOOK T1 - Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis Y1 - 2019/04// PY - 2019/6/18/pubmed PY - 2019/6/18/medline PY - 2019/6/18/entrez N2 - The objective of this review is to perform a systematic review of the beneficial and harmful effects of edaravone for the treatment of amyotrophic lateral sclerosis. PB - Canadian Agency for Drugs and Technologies in Health CY - Ottawa (ON) UR - https://www.unboundmedicine.com/medline/citation/31206286/Clinical_Review_Report:_Edaravone_(Radicava):_(Mitsubishi_Tanabe_Pharma_Corporation):_Indication:_For_the_treatment_of_amyotrophic_lateral_sclerosis L2 - https://www.ncbi.nlm.nih.gov/books/NBK542359 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows